- Hodnocení účinosti snížené pokračovací dávky agalsidase beta po standardní dávce enzymatické substituční terapie u pacientů s Fabryho chorobou2009 | 1. lékařská fakulta
- Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis2020 | 1. lékařská fakulta
- Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial2019 | 1. lékařská fakulta
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study2023 | 1. lékařská fakulta
- Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: Data from the Fabry Registry2016 | 1. lékařská fakulta
- Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch2014 | Ústřední knihovna
- Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community2023 | 1. lékařská fakulta
- Léčba Fabryho choroby - agalsidáza alfa versus agalsidáza beta, mezinárodní studie : komentář2018 | 1. lékařská fakulta
- Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial2015 | 1. lékařská fakulta
- The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts2019 | 1. lékařská fakulta
- The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease2007 | 3. lékařská fakulta
- Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus2021 | 1. lékařská fakulta